STOCK TITAN

AstraZeneca PLC - AZN STOCK NEWS

Welcome to our dedicated page for AstraZeneca PLC news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.

AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.

The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.

Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.

Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.

With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.

Rhea-AI Summary

AstraZeneca’s FARXIGA (dapagliflozin) has received Priority Review status from the FDA for treating chronic kidney disease (CKD) in adults, with or without type 2 diabetes. This review reflects the potential of FARXIGA to significantly improve patient outcomes. The FDA aims for a decision by Q2 2021. In clinical trials, FARXIGA reduced the risk of worsening renal function or cardiovascular death by 39% and overall mortality by 31%. This treatment, already indicated for diabetes and heart failure, has shown promising efficacy according to the DAPA-CKD Phase III trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
Rhea-AI Summary

AstraZeneca's TAGRISSO® (osimertinib) has received approval from the US FDA for adjuvant treatment in adult patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) post-tumor resection. The decision was supported by the ADAURA Phase III trial, which showed an 83% reduction in disease recurrence risk for Stage II and IIIA patients. The treatment demonstrated a 89% disease-free survival rate at two years compared to 52% for placebo. TAGRISSO's approval also involved five international health authorities through Project Orbis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
Rhea-AI Summary

AstraZeneca and Daiichi Sankyo presented updated results from the DESTINY-Breast01 trial for ENHERTU (fam-trastuzumab deruxtecan-nxki), showing continued efficacy in HER2-positive metastatic breast cancer patients. With a median follow-up of 20.5 months, the trial indicated a 61.4% objective response rate (ORR) and a median duration of response of 20.8 months. The median progression-free survival was 19.4 months, and 74% of patients remained alive at 18 months. The treatment demonstrated consistent safety profiles, though 18.5% discontinued due to adverse events. ENHERTU is approved in the US and Japan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
Rhea-AI Summary

A pooled analysis of 762 CLL patients treated with CALQUENCE (acalabrutinib) monotherapy showed a low incidence of cardiac adverse events (AEs) leading to treatment discontinuation. At a median follow-up of 25.9 months, 17% reported cardiac AEs, with only 0.9% discontinuing treatment due to these issues. The analysis concluded that CALQUENCE has a favorable cardiovascular safety profile, akin to untreated CLL patient populations. AstraZeneca plans further trials for CALQUENCE in CLL, aiming to enhance treatment efficacy and safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
Rhea-AI Summary

Long-term follow-up data from the ACE-LY-004 Phase II trial showed CALQUENCE® (acalabrutinib) effectively treats relapsed or refractory mantle cell lymphoma (MCL). Patients achieved a median progression-free survival of 22 months, with overall survival data still pending after three years. The trial included 124 patients, demonstrating a 28.6% overall response rate and 41.9% estimated duration of response at 36 months. The safety profile remained stable, with 11% discontinuing due to adverse events. CALQUENCE is an important treatment option, particularly as MCL is aggressive and typically diagnosed late.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

AstraZeneca is set to present new findings on breast cancer therapies at the 2020 San Antonio Breast Cancer Symposium (SABCS) from December 8-11. Key highlights include updated data from the DESTINY-Breast01 Phase II trial, showcasing ENHERTU's efficacy in HER2-positive metastatic breast cancer, and promising results from the SERENA-1 Phase I trial evaluating AZD9833 in HR-positive, HER2-negative advanced breast cancer. AstraZeneca emphasizes its commitment to improving outcomes for breast cancer patients through innovative treatments and collaborations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary

AstraZeneca's IMFINZI® (durvalumab) has received FDA approval for a new 1,500mg fixed dosing option every four weeks for patients with unresectable Stage III non-small cell lung cancer (NSCLC) post-chemoradiation and previously treated advanced bladder cancer. This alternative to the current weight-based dosing aims to improve patient convenience and reduce healthcare visits. This decision follows the FDA's Priority Review status and is based on data from pivotal clinical trials, including the PACIFIC and CASPIAN studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
Rhea-AI Summary

AstraZeneca will showcase new research at the 62nd ASH Annual Meeting from December 5-8, 2020, focusing on blood cancers. The Company is presenting 27 abstracts related to five medicines, including CALQUENCE. Highlights include a pooled analysis of CALQUENCE’s cardiovascular safety in CLL, promising follow-up data in MCL, and findings on roxadustat for various anemia conditions. The data aim to address unmet needs in hematology and demonstrate AstraZeneca's commitment to improving treatments for patients with hematologic malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
Rhea-AI Summary

A recent study highlights that 81.1% of patients with NYHA class II-IV heart failure with reduced ejection fraction (HFrEF) may qualify for treatment with FARXIGA (dapagliflozin). This data was presented at the AHA’s Scientific Sessions 2020, based on over 150,000 patient records from U.S. hospitals. FARXIGA is FDA-approved to lower cardiovascular death and hospitalization risks in adults with HFrEF. The study underscores the urgent need for clinical practice to adopt this treatment, ultimately aiming to fill gaps in care for heart failure patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none

FAQ

What is the current stock price of AstraZeneca PLC (AZN)?

The current stock price of AstraZeneca PLC (AZN) is $66.3 as of December 24, 2024.

What is the market cap of AstraZeneca PLC (AZN)?

The market cap of AstraZeneca PLC (AZN) is approximately 205.6B.

What is AstraZeneca PLC?

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It is headquartered in Cambridge, England.

What therapeutic areas does AstraZeneca focus on?

AstraZeneca’s product portfolio includes drugs across several therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Where does AstraZeneca generate most of its revenue?

A significant portion of AstraZeneca’s revenue comes from international markets, with the United States accounting for nearly one-third of its sales.

What is the recent collaboration between AstraZeneca and Nona Biosciences about?

AstraZeneca and Nona Biosciences have entered into a global license agreement to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology.

What is C-CAR031?

C-CAR031 is a GPC3-targeted CAR-T therapy developed by AstraZeneca and AbelZeta Pharma for treating hepatocellular carcinoma (HCC). Initial clinical results have shown promising safety and efficacy data.

What is rilvegostomig?

Rilvegostomig is a PD-1/TIGIT bispecific antibody developed by AstraZeneca in collaboration with Compugen Ltd. It is currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer.

What are some of AstraZeneca’s key recent achievements?

Recent achievements include a global license agreement with Nona Biosciences for oncology therapies, collaboration with AbelZeta Pharma on C-CAR031, and partnership with Compugen Ltd. for developing rilvegostomig.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered at the Cambridge Biomedical Campus in Cambridge, England.

When was AstraZeneca formed?

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK.

What is the focus of AstraZeneca’s research and development?

AstraZeneca focuses on research and development in pharmaceuticals and biotechnology, particularly in creating treatments for various major therapeutic areas including cancer, respiratory diseases, cardiovascular conditions, and more.

AstraZeneca PLC

NYSE:AZN

AZN Rankings

AZN Stock Data

205.57B
3.10B
0.01%
16.76%
0.26%
Drug Manufacturers - General
Healthcare
Link
United States of America
Cambridge